Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human multiple-part study of LOU064 in healthy volunteers and adults with atopic dermatitis
NL-OMON46164Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing LOU064 with Placebo (2 arms). Primary endpoints: Adverse events, Physical examination and anamnesis and 4 more. Started Mar 2019; status: completed.
02
Drugs
remibrutinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON46164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46164.